Summary
The frequency of gallstones during longterm treatment with the somatostatin analogue octreotide reported in different studies varies from 0% to 50%, the reason for this variation being unknown. Therefore, we examined 58 acromegalic patients undergoing different treatment regimens for the frequency of gallstones. Thirteen were treated with octreotide, 20 with bromocriptine, and 25 had no medical treatment after successful neurosurgery. Also, 58 patients without known gallbladder disease served as controls. The postprandial gallbladder contraction was also investigated in 27 acromegalic patients (10 with octreotide, 10 with bromocriptine, and 7 with no medical therapy). Ten of the 58 acromegalic patients were found to have gallstones, 4 of 25 receiving no medical treatment, 4 of 20 treated with dopamine agonists, and 2 of 13 treated with octreotide. In 9 of the 58 control patients, gallstones were detected. Although in the octreotide group the gallstones were newly formed under therapy, there was no difference in gallstone prevalence between the different treatment regimens and the control group. However, the postprandial gallbladder contraction was significantly more often inhibited during octreotide therapy, and this effect was most pronounced during the first hours following injection. Differences in the timing of injections therefore may be an explanation of the variable incidence of cholelithiasis in the different studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- SD:
-
standard deviation
- Sm-C:
-
somatomedinC
References
Fisher RS, Rock E, Levin G, Malmud L (1987) Effects of somatostatin on gallbladder emptying. Gastroenterology 92:885–890
Ho KY, Weissenberger AJ, Marbach P, Lazarus L (1990) Therapeutic efficacy of the somatostatin analog SMS 201–995 octreotide in acromegaly effects of dose and frequency and long-term safety. Ann Intern Med 112:173–181
Hopman WP, Liessum PA van, Pieters GF, Smals AG, Tangerman A, Jansen JB, Rosenbusch G, Lamers CB, Kloppenburg PW (1990) Pancreatic exocrine and gallbladder function during long-term treatment with octreotide (SMS 201–995). Digestion 45 [Suppi 1]:72–76
Hornbostel H, Wurbs D (1986) Erkrankungen der Gallenwege. In: Hornbostel H, Kaufmann W, Siegenthaler W (eds) Innere Medizin and Klinik. Thieme, Stuttgart, pp 15.199–15.213
Liessum PA van, Hopman WP, Pieters GF, Jansen JB, Smals AG, Rosenbusch G, Kloppenburg PW, Lamers CB (1989) Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201–995 in acromegaly. J Clin Endocrinol Metab 69:557–562
Marteau P, Chretien Y, Calmus Y, Pare R, Poupon R (1989) Pharmacological effect of somatostatin on bile secretion in man. Digestion 42:16–21
Page MD, Millward ME, Hourihan M, Hall R, Scanlon NF (1990) Long-term treatment of acromegaly with octreotide (Sandostatin). Horm Res 33 [Suppl 1]:20–30
Palasciano G, Portincasa P, Vinciguerra V, Velardi A, Tardi S, Baldassarre G, Albano O (1989) Gallstone prevalence and gallbladder volume in children and adolescents: an epidemiological ultrasonographic survey and relationship to body mass index. Am J Gastroenterol 84:1378–1382
Salmela PI, Juustila H, Pyhtinen J, Jokinen K, Alavaiokko M, Ruokonen A (1990) Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-1, and the amino-terminal propeptide of type III procollagen in acromegaly. J Clin Endocrinol Metab 70:1193–1201
Sassolas G, Fossati P, Chanson P, Costa R, Estour B, Deidier A, Harris AG (1989) Experience of a six-month treatment with sandostatin at increasing doses in acromegaly. Horm Res 31:51–54
Schmidt K, Althoff PH, Harris AG, Hofmeister-Wagner W, Schifferdecker E, Schöffling K (1990) Langzeitbehandlung der Akromegalie mit dem Somatostatinanalogon Octreotid (Sandostatin). Med Klin 85:700–706
Shi YF, Harris AG, Zhu XF, Deng JY (1990) Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201–995 in ten acromegalic patients. Clin Endocrinol 32:695–706
Tauber JP, Babin T, Tauber MT, Vigoni F, Bonafe A, Ducasse M, Harris AG, Bayard F (1989) Long term effects of continuous subcutaneous infusions of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab 68:917–924
Wass JA (1990) Octreotide treatment of acromegaly. Horm Res 33 [Suppl 1]:1–5
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmidt, K., Leuschner, M., Harris, A.G. et al. Gallstones in acromegalic patients undergoing different treatment regimens. Clin Investig 70, 556–559 (1992). https://doi.org/10.1007/BF00184790
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00184790